FTC Sues to Block Merger of Rivals Developing Treatment for Faulty Aortic Valves

A year ago, three firms were racing to bring transcatheter aortic valve replacement devices to market. The FTC said allowing Edwards Lifesciences to buy JenaValve would reduce that number to one.

       

A year ago, three firms were racing to bring transcatheter aortic valve replacement devices to market. The FTC said allowing Edwards Lifesciences to buy JenaValve would reduce that number to one.